| | SLO | ENG | Cookies and privacy

Bigger font | Smaller font
First page > Show document

Show document Help

Title:Uporaba bioloških zdravil v Univerzitetnem kliničnem centru Maribor
Authors:ID Bavec, Andrej (Author)
ID Krajnc, Ivan (Author)
Files:.pdf Zdravniski_vestnik_2008_Bavec,_Krajnc_Uporaba_bioloskih_zdravil_v_Univerzitetnem_klinicnem_centru_Maribor.pdf (124,03 KB)
MD5: 57A5D570ECFA79A80AC4C79C41E3F577
 
URL http://vestnik.szd.si/index.php/ZdravVest/article/view/500
 
Language:Slovenian
Work type:Scientific work
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Abstract:Izhodišča: Posamezna biološka zdravila, kljub specifičnemu delovanju na določene tarče, pokrivajo zelo širok spekter možnosti uporabe pri zdravljenju različnih bolezni, a se klinična uporaba omejuje na ozke, točno določene indikacije. Najbolj pogosto se uporabljajo po standardnem zdravljenju, ki ni bilo uspešno. Metode: Z raziskavo je bila analizirana uporaba bioloških zdravil v klinični praksi predvsem po indikacijskih področjih na Oddelku za revmatologijo, Oddelku za hematologijo, Oddelku za gastroenterologijo in endoskopijo Klinike za interno medicino, Oddelku za kožne in spolne bolezni ter na Oddelku za ginekološko onkologijo in onkologijo dojk Klinike za ginekologijo in perinatologijo Univerzitetnega kliničnega centra Maribor. Rezultati: V proučevanem obdobju so se biološka zdravila uporabljala pri zdravljenju 195 bolnikov, in sicer vsa trenutno registrirana biološka zdravila, razen abatacepta, anakinre in bevacizumaba. Največ (86) bolnikov se je zdravilo z infliximabom, etanerceptom in adalimumabom na Oddelku za revmatologijo, najpogosteje zaradi revmatoidnega artritisa in ankilozirajočega spondilitisa. 69 bolnic se je s trastuzumabom zdravilo zaradi raka dojke. Na Oddelku za hematologijo so z rituximabom, ibritumomab tiukseatanom, alemtuzumabom in bortezomibom skupaj zdravili 14 bolnikov z ne-Hodgkinovimi limfomi, B-celično kronično limfocitno levkemijo ter plazmocitomom. Z infliximabom je bilo zdravljenih 13 bolnikov s Crohnovo boleznijo ali ulceroznim kolitisom. Zaradi psoriaze s plaki se je z efalizumabom zdravilo 11 in z infliximabom 2 bolnika. Zaključki: S pogostejšo uporabo bioloških zdravil pri bolnikih z različnimi pridruženimi boleznimi lahko pričakujemo razširitev indikacij za zdravljenje. Na osnovi novejših raziskav lahko v klinični praksi pričakujemo uporabo bioloških zdravil v zgodnejšem obdobju bolezni in razvoj novih bioloških zdravil, ki bodo delovala na nove tarče v patogenezi bolezni.
Keywords:biološka zdravila, zdravljenje, revmatoidni artritis, psoriaza, kronična črevesna vnetna bolezen, ne-Hodgkinov limfom, plazmocitom, rak dojke
Publication status:Published
Publication version:Version of Record
Year of publishing:2008
Number of pages:str. 561-571
Numbering:Letn. 77, št. 9
PID:20.500.12556/DKUM-65289 New window
ISSN:1318-0347
UDC:615.27
ISSN on article:1318-0347
COBISS.SI-ID:3095359 New window
NUK URN:URN:SI:UM:DK:TQNGKMOO
Publication date in DKUM:28.03.2017
Views:2118
Downloads:169
Metadata:XML DC-XML DC-RDF
Categories:Misc.
:
BAVEC, Andrej and KRAJNC, Ivan, 2008, Uporaba bioloških zdravil v Univerzitetnem kliničnem centru Maribor. Zdravniški vestnik. glasilo Slovenskega zdravniškega društva [online]. 2008. Vol. 77, no. 9, p. 561–571. [Accessed 21 March 2025]. Retrieved from: https://dk.um.si/IzpisGradiva.php?lang=eng&id=65289
Copy citation
  
Average score:
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
(0 votes)
Your score:Voting is allowed only for logged in users.
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Zdravniški vestnik. glasilo Slovenskega zdravniškega društva
Publisher:Slovensko zdravniško društvo
ISSN:1318-0347
COBISS.SI-ID:32893696 New window

Licences

License:CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:http://creativecommons.org/licenses/by-nc/4.0/
Description:A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.
Licensing start date:28.03.2017

Secondary language

Language:English
Title:Use of biological agents at University clinical center Maribor
Abstract:Background: Individual biological agents, despite their specific activity on targets, cover very broad spectrum of possibilities for use in treatment of different diseases. Their clinical use is limited to exact indications with criteria of use. Biological agents are most frequently indicated and used for the treatment of diseases, which were unsuccessfully treated with standard therapy. Methods: Use of biological agents in clinical practice at Department of rheumatology, Department of hematology, Department of gastroenterology at Clinic of internal medicine, Department of skin and venereal diseases and Department of gynecologic and breast oncology at Clinic of gynecology and perinatology was analyzed. Results: Biological agents were used for the treatment of 195 patients. All currently registered biological agents were used except anakinra, abatacept and bevacizumab. Most (86) patients were treated with infliximab, etanercept and adalimumab at the Department of rheumatology, the most frequently because of rheumatoid arthritis and ankylosing spondylitis. 69 patients were treated with trastuzumab because of breast cancer. 14 patients were treated with rituximab, ibritumomab tiukseatan, alemtuzumab and bortezomib at the Department of hematology because of non-Hodgkin lymphoma, B-cell chronic lymphocytic leukemia and multiple myeloma. 13 patients with Crohn's disease or ulcerative colitis were treated with infliximab. 11 patients were treated with efalizumab and 2 with infliximab because of psoriasis. Conclusions: Expansion of therapeutic indications is expected with more frequent use of biological agents in patients with different associated diseases. Use of biological agents earlier in the course of disease and development of new biologics, with effect on new targets in pathogenesis of diseases, can be expected on the basis of new researches.
Keywords:biological agents, therapy, rheumatoid arthritis, psoriasis, chronic inflammatory bowel disease, non-Hodgkin lymphoma, multiple myeloma, breast cancer


Comments

Leave comment

You must log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back
Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica